Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Bhojwani

Showing results (81-90 of 125) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoidsSue C Kaste, Deqing Pei, Cheng Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Deepa Bhojwani, Huining Kang, Renee X Menezes, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Frontiers in Oncology|December 20, 2021
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaYongsheng Ruan, Hye Na Kim, Heather A Ogana, et al.
Cancer|August 19, 2020
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemiaSeth E Karol, Todd M Cooper, Paul E Mead, et al.
Journal of the National Cancer Institute|July 4, 2024
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortiumEric S Schafer, Teresa Rushing, Kristine R Crews, et al.
Blood Advances|August 15, 2025
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group reportJohn A Ligon, Lingyun Ji, Alice Dang, et al.
Pageof 13

Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoidsSue C Kaste, Deqing Pei, Cheng Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Deepa Bhojwani, Huining Kang, Renee X Menezes, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Frontiers in Oncology|December 20, 2021
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaYongsheng Ruan, Hye Na Kim, Heather A Ogana, et al.
Cancer|August 19, 2020
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemiaSeth E Karol, Todd M Cooper, Paul E Mead, et al.
Journal of the National Cancer Institute|July 4, 2024
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortiumEric S Schafer, Teresa Rushing, Kristine R Crews, et al.
Blood Advances|August 15, 2025
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group reportJohn A Ligon, Lingyun Ji, Alice Dang, et al.
Pageof 13